Abstract
Background: Mild cognitive impairment (MCI) is a syndrome heterogeneous with regards to etiology and prognosis. Amyloid imaging enables to visualize a hallmark pathology of Alzheimer’s disease (AD). Therefore we aimed to assess the usefulness of [11C]PiB PET for predicting clinical outcome of MCI patients after an interval of 2 years.
Methods: In 28 MCI participants with a global CDR rating at baseline of 0.5 a baseline examination including clinical assessments and [11C]PiB PET imaging and a clinical follow-up examination after a planned interval of 24 months were performed. Predictive values and accuracy of amyloid-positive and negative scans for conversion to dementia of any type and to dementia due to AD were calculated and compared to neuropsychological tests and ApoE genotyping.
Results: Of 17 MCI patients who were amyloid-positive at baseline converted 9 to dementia all of the AD type. 3 of the 11 amyloid-negative MCI subjects converted to dementia but none to dementia due to AD. PPV, NPV and accuracy (to dementia: 0.53, 0.73 and 0.61; to AD: 0.53, 1.00 and 0.70) was comparable to neuropsychological tests and superior to ApoE genotyping.
Conclusion: All MCI subjects who converted to dementia due to AD were amyloid-positive. However, only 50% of these MCI due to AD, intermediate likelihood, patients developed manifest dementia due to AD after 24 months limiting the usefulness of [11C]PiB PET for individual prediction of clinical outcome.
Keywords: Mild cognitive impairment, positron emission tomography, pittsburgh compound b, prospective study, conversion.
Current Alzheimer Research
Title:The Usefulness of Amyloid Imaging in Predicting the Clinical Outcome After Two Years in Subjects with Mild Cognitive Impairment
Volume: 10 Issue: 1
Author(s): Timo Grimmer, Carolin Wutz, Alexander Drzezga, Stefan Förster, Hans Förstl, Marion Ortner, Robert Perneczky and Alexander Kurz
Affiliation:
Keywords: Mild cognitive impairment, positron emission tomography, pittsburgh compound b, prospective study, conversion.
Abstract: Background: Mild cognitive impairment (MCI) is a syndrome heterogeneous with regards to etiology and prognosis. Amyloid imaging enables to visualize a hallmark pathology of Alzheimer’s disease (AD). Therefore we aimed to assess the usefulness of [11C]PiB PET for predicting clinical outcome of MCI patients after an interval of 2 years.
Methods: In 28 MCI participants with a global CDR rating at baseline of 0.5 a baseline examination including clinical assessments and [11C]PiB PET imaging and a clinical follow-up examination after a planned interval of 24 months were performed. Predictive values and accuracy of amyloid-positive and negative scans for conversion to dementia of any type and to dementia due to AD were calculated and compared to neuropsychological tests and ApoE genotyping.
Results: Of 17 MCI patients who were amyloid-positive at baseline converted 9 to dementia all of the AD type. 3 of the 11 amyloid-negative MCI subjects converted to dementia but none to dementia due to AD. PPV, NPV and accuracy (to dementia: 0.53, 0.73 and 0.61; to AD: 0.53, 1.00 and 0.70) was comparable to neuropsychological tests and superior to ApoE genotyping.
Conclusion: All MCI subjects who converted to dementia due to AD were amyloid-positive. However, only 50% of these MCI due to AD, intermediate likelihood, patients developed manifest dementia due to AD after 24 months limiting the usefulness of [11C]PiB PET for individual prediction of clinical outcome.
Export Options
About this article
Cite this article as:
Grimmer Timo, Wutz Carolin, Drzezga Alexander, Förster Stefan, Förstl Hans, Ortner Marion, Perneczky Robert and Kurz Alexander, The Usefulness of Amyloid Imaging in Predicting the Clinical Outcome After Two Years in Subjects with Mild Cognitive Impairment, Current Alzheimer Research 2013; 10 (1) . https://dx.doi.org/10.2174/1567205011310010011
DOI https://dx.doi.org/10.2174/1567205011310010011 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Mechanisms, Proteinopathies and Therapeutic Strategies in Neurodegenerative Disorders
Current Genomics Antimetastatic Potential of Quercetin Analogues with Improved Pharmacokinetic Profile: A Pharmacoinformatic Preliminary Study
Anti-Cancer Agents in Medicinal Chemistry Dementia and the Default Mode
Current Alzheimer Research Potential Effect of Anti-Tumour Necrosis Factor-Alpha Treatment on Reducing the Cardiovascular Risk Related to Rheumatoid Arthritis
Current Vascular Pharmacology PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
Current Pharmaceutical Design Cognitive Dysfunction in FMR1 Premutation Carriers
Current Psychiatry Reviews Lentiviral Vector-Based Models of Amyloid Pathology: From Cells to Animals
Current Alzheimer Research BK Channel Modulators: A Comprehensive Overview
Current Medicinal Chemistry The Role of the Brain Renin-Angiotensin System in Neurodegenerative Disorders
Current Alzheimer Research The Genetics of Small-Vessel Disease
Current Medicinal Chemistry Cholesterol and Alzheimers Disease: Clinical and Experimental Models Suggest Interactions of Different Genetic, Dietary and Environmental Risk Factors
Current Drug Targets Optimized Turmeric Extracts have Potent Anti-Amyloidogenic Effects
Current Alzheimer Research Antihypertensive Therapy: Role of Aldosterone Antagonists
Current Pharmaceutical Design Advances in Drug Delivery from Nose to Brain: An Overview
Current Drug Therapy Methamphetamine and HIV Infection, Role in Neurocognitive Dysfunction
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry New Devices for Treating Acute Ischemic Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Past and Recent Progress of Molecular Imaging Probes for β-Amyloid Plaques in the Brain
Current Medicinal Chemistry Strategies for Continued Successful Treatment in Patients with Alzheimer’s Disease: An Overview of Switching Between Pharmacological Agents
Current Alzheimer Research Recent Progress in Anticonvulsant Drug Research: Strategies for Anticonvulsant Drug Development and Applications of Antiepileptic Drugs for Non-Epileptic Central Nervous System Disorders
Current Topics in Medicinal Chemistry Novel Therapeutic Agents in the Management of Hemorrhage and Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry